



HYBRIDOMA TECHNOLOGY: A REVIEW

Sunita Sharma

NRI Vidyayani Institute of Science, Management and Technology

Abstract: Hybridoma innovation is the strategy in which expansive amount of indistinguishable antibodies are delivered which are otherwise called monoclonal antibodies. It is finished by the organization of antigen in mouse which creates a resistant reaction. The B-cells creating antibodies are then reaped from the infused mouse. The gathered B-cells are then melded with B malignancy cells which stay undying. This produces cross breed cell line called hybridoma which has the neutralizer creating capacity of the B-cell. The hybridomas can be developed in culture with one suitable cell which produces societies having hereditarily indistinguishable hybridomas. It produces monoclonal antibodies. It holds the capacity to develop in tissue culture and don't have counter acting agent delivering ability.

Keywords B-cells, Hybridoma, Monoclonal antibodies

Introduction: The generation of monoclonal antibodies was concocted by César Milstein and Georges J. F. Köhler in 1975. They shared the Nobel Prize of 1984 for Medicine and Physiology with Niels Kaj Jerne, who made different commitments to immunology.¹ Procedure Laboratory creatures like mice are managed with a progression of infusions of the test antigen for a little while against which the

immunizer is to be produced. The splenocytes are disconnected from the mouse spleen and the B cells are intertwined with deified myeloma cells by the procedure of electrofusion. Then again, synthetic reagent like polyethylene glycol is utilized for the combination of B-cells and myelomas. The myeloma cells are chosen which do not have the hypoxanthine-guanine phosphoribosyltransferase (HGPRT) quality, making them touchy to the HAT medium.² The melded cells are brooded in HAT medium (hypoxanthine-aminopterin-thymidine medium) for around 10 to 14 days. The unfused myeloma cells are expelled as they can exceed different cells, particularly pitifully settled hybridomas. Unfused B cells kick the bucket as they have a

For Correspondence:

researcharticle78@gmail.com.

Received on: January 2017

Accepted after revision: March 2017

Downloaded from: www.johronline.com

short life expectancy. By this strategy the B cell-myeloma crossovers survive. At that point the weakening of the hatched medium is completed in 96-well plates. The B-cells deliver the antibodies and are coordinated towards a similar epitope, and are therefore monoclonal antibodies.³

Hybridomas are cells that have been built to deliver a coveted immunizer in expansive sums, to create monoclonal antibodies. (1, 2) Monoclonal antibodies can be delivered in particular cells through a method now prevalently known as hybridoma technology.¹ Hybridoma innovation was found in 1975 by two researchers, Georges Kohler of West Germany and Cesar Milstein of Argentina (now working in U.K.), who together with Niels Jerne of Denmark (now working in Germany) were granted the 1984 Noble prize for physiology and medicine.¹ Generally, the creation of one MAb, utilizing the hybridoma innovation, costs amongst \$8,000 and \$12,000. The normal sensibly SK can create just 15 to 30 hybridoma combinations for each year, however in a domain where the emphasis is on demonstrative or remedial quality MAbs, there are extra huge impediments than can additionally diminish throughput. Monoclonal antibodies is profitable for the investigation of parasites antigen and fitting that WHO ought to have composed a symposium (held at the national college of Singapore, October 1981) which united the individuals who have set up and refined the innovation and the individuals who are utilizing it, or expecting to utilize it for the investigation of creature in charge of a portion of the significant illnesses influencing humankind. Such monoclonal antibodies, as they are known, have opened exceptional new ways to deal with anticipating, diagnosing, and treating infection. Monoclonal antibodies are utilized, for example, to recognize subsets of B cells and T cells. This learning is useful for essential research as well as for distinguishing diverse sorts of leukemias and lymphomas and permitting doctors to tailor treatment as needs

be. Quantitating the quantity of B cells and assistant T cells is terrifically critical in invulnerable issue, for example, AIDS. Monoclonal antibodies are being utilized to track growth antigens and, alone or connected to anticancer operators, to assault malignancy metastases. The monoclonal immunizer known as OKT3 is sparing organ transplants undermined with dismissal, and keeping bone marrow transplants from setting off joint versus-have infection (insusceptible framework arrangement).

Methodology: A hybridoma, which can be considered as a harry cell, is created by the infusion of a particular antigen into a mouse, securing the antigen-particular plasma cells (counter acting agent delivering cell) from the mouse's spleen and the resulting combination of this phone with a malignant resistant cell called a myeloma cell. The half breed cell, which is in this way created, can be cloned to deliver numerous indistinguishable little girl clones. These little girl clones then discharge the invulnerable cell item. Since these antibodies originate from just a single sort of cell (the hybridoma cell) they are called monoclonal antibodies. The upside of this procedure is that it can join the characteristics of the two distinct sorts of cells; the capacity to develop persistently, and to create a lot of unadulterated immune response. Cap medium (Hypoxanthine Aminopettrin Thymidine) is utilized for planning of monoclonal antibodies. Research center creatures (eg. mice) are initially presented to an antigen to which we are keen on segregating a counter acting agent against. When splenocytes are secluded from the warm blooded creature, the B cells are melded with deified myeloma cells - which do not have the HGPRT(hypoxanthine-guanine phosphoribosyltransferase) quality - utilizing polyethylene glycol or the Sendai infection. Intertwined cells are brooded in the HAT (Hypoxanthine Aminopettrin Thymidine) medium. Aminopterin in the myeloma cells kick the bucket, as they can't create nucleotides by

the new or rescue medium obstructs the pathway that takes into consideration nucleotide amalgamation. Subsequently, unfused D cell kick the bucket. Unfused B cells bite the dust as they have a short life expectancy. Just the B cell-myeloma half and halves get by, since the HGPRT quality originating from the B cells is practical. These cells deliver antibodies (a property of B cells) and are interminable (a property of myeloma cells). 2 The brooded medium is then weakened into multiwell plates to such a degree, to the point that each well contains just 1 cell. At that point the supernatant in each well can be checked for craved counter acting agent. Since the antibodies in a well are created by a similar B cell, they will be coordinated towards a similar epitope, and are known as monoclonal antibodies.³ Once a hybridoma province is set up, it will consistently develop in culture medium like RPMI-1640 (with anti-toxins and fetal cow-like serum) and deliver counter acting agent (Nelson et al., 2000.)³ The following stage is a fast essential screening process, which recognizes and chooses just those hybridomas that create antibodies of proper specificity. The hybridoma culture supernatant, auxiliary compound marked conjugate, and chromogenic substrate, is then brooded, and the development of a shaded item demonstrates a positive hybridoma. On the other hand, immunocytochemical screening can likewise be utilized (Nelson et al., 2000.)³ Multiwell plates are utilized at first to develop the hybridomas and after choice, are changed to bigger tissue culture carafes. This keeps up the prosperity of the hybridomas and gives enough cells to cryopreservation and supernatant for resulting examinations. The way of life supernatant can yield 1 to 60 ug/ml of monoclonal neutralizer, which is kept up at 20°C or lower until required (Nelson et al., 2000.) By utilizing society supernatant or a refined immunoglobulin arrangement, facilitate examination of a potential monoclonal counter acting agent creating hybridoma can be made as far as reactivity, specificity, and crossreactivity

(Nelson et al., 2000.)³

Advancements OR Improvements in Hybridoma Technology – Considerable efforts during the last 10-15 years have been made to improve the yield of monoclonal antibodies using hybridoma technology^{4, 5}. These efforts included the following: (6, 7) (1) The substitution of a chemical fusion promoter (P.E.G.) for the Sendai virus initially used to promote fusion, and (2) The use of myelomas that do not secrete their own antibodies and that therefore do not interfere with the production of the required antibody (3) A continuous cell line (Sp 2/0) was used as a fusion partner for the antibody producing B cells. (4) Feeder layers consisting of extra cells to feed newly formed hybridomas were used for optimal growth and hybridoma production.

Purification of Antibodies: Monoclonal antibodies may should be purged before they are utilized for an assortment of purposes. Before conclusive sanitization, the way of life might be subjected to cell fractionation for improvement of the immune response protein. In E. coli, the antibodies might be discharged in the periplasm, which might be utilized for advancement of neutralizer, so that further decontamination is disentangled. On the other hand the antibodies might be cleansed from cell homogenate or cell trash acquired from the medium. (6, 7) Antibodies can be refined by anybody of the accompanying systems (i) particle trade chromatography; (ii) antigen partiality chromatography. Serum Free Media for Bulk Culture of Hybridoma Cells – The media for refined an assortment of creature cells and talked about the noteworthiness of adding serum to basal supplement media. Serum is a profoundly intricate and inadequately characterized blend of segments like egg whites, transferrin, lipoproteins and different hormones/development variables. By the by, serum makes a basic part of media for refined creature cells. The utilization of serum, notwithstanding, prompts challenges in cleansing of antibodies. Advances, it is a costly

innovation for expansive scale creation of hybridoma cells for mechanical generation of monoclonal antibodies. In perspective of these challenges, serum free media are in effect progressively utilized for refined hybridoma cells. (6, 7) Advantages of Serum Free Media in Hybridoma Cell Culture and Preparation of Monoclonal Antibodies: (6, 7) 1. Enormously rearranged sanitization of antibodies because of expanded 1.initial immaculateness and nonappearance of debasing immunoglobulin. 2. Diminished fluctuation of culture medium. 3. Diminished danger of irresistible operators. 4. Less factors for quality control/quality confirmation. 5. Expanded control over bioreactor conditions. 6. Potential for expanded counter acting agent emission. 7. Low or no reliance on creatures. 8. Financially savvy. 9. General upgraded productivity Disadvantages of Serum Free Media in Hybridoma Cell Culture and Preparation of Monoclonal Antibodies-1. Not all serum free media are material to all cell lines. 2. Cells may not develop to as high densities and might be more delicate than cells in serum 3. Media may take more time to plan. Bypassing Hybridomas and Cloning of mab Genes – The VH and VL qualities for antibodies can be enhanced through polymerase chain response (PCR) utilizing 'all inclusive groundworks' (general preliminaries will convey monitored successions for generally antibodies). By building limitation locales in the above preliminaries, the enhanced VH and VL qualities can likewise be cloned specifically for expression in mammalian cells or microbes. The crude material for PCR might be hybridomas or B cells, which might be homogeneous (if gotten from single cells) or heterogeneous. In the last case, an assortment of VH and VL qualities will be intensified and will consolidate indiscriminately to create upwards of 106 clones for neutralizer qualities (from 1000 diverse VH and 1000 distinctive VL qualities). These qualities will be cloned in a phage and their items (especially Fab sections) can be screened for antigen restricting exercises. From

such a substantial number of blends in a combatorial library, it is exceptionally hard to recuperate the first combines of V qualities (e.g. VHa.VLa or VHx.VLx is a unique match: VLy is another mix VHa). Be that as it may, the many-sided quality might be decreased by utilizing antigen-chose B lymphocytes (channels covered with antigen can be utilized for screening). (7) Designing and Building of mab Genes – The antigen restricting destinations of antibodies have been contemplated in some detail as of late. This prompted demonstrating of totally new antibodies, here and there for their utilization as proteins. This demonstrating through PC illustrations can be utilized for adjustment of neutralizer qualities or for union of altogether qualities. These qualities can be cloned and communicated in microscopic organisms. The antibodies delivered can be tried for their specificity and liking for particular antigen. (7) Primary and Secondary Libraries for Antibody Genes – In this technique a collection of counter acting agent qualities can be set up by utilizing qualities that can be gotten from various distinctive sources including the accompanying (i) Rearranged V qualities from creatures got using PCR (with general preliminaries) (ii) New V qualities got through quality change, a procedure received in fowls (iii) Rearranged qualities acquired from mRNA through turn around interpretation (iv) Designing altogether new V qualities or D sections. The following stride is to permit the outflow of library in microbes and screen antibodies for antigen restricting exercises.

MabCure hybridoma technology: Monoclonal antibodies may should be purged before they are utilized for an assortment of purposes. Before conclusive sanitization, the way of life might be subjected to cell fractionation for improvement of the immune response protein. In E. coli, the antibodies might be discharged in the periplasm, which might be utilized for advancement of neutralizer, so that further decontamination is disentangled. On the other

hand the antibodies might be cleansed from cell homogenate or cell trash acquired from the medium. (6, 7) Antibodies can be refined by anybody of the accompanying systems (i) particle trade chromatography; (ii) antigen partiality chromatography. Serum Free Media for Bulk Culture of Hybridoma Cells – The media for refined an assortment of creature cells and talked about the noteworthiness of adding serum to basal supplement media. Serum is a profoundly intricate and inadequately characterized blend of segments like egg whites, transferrin, lipoproteins and different hormones/development variables. By the by, serum makes a basic part of media for refined creature cells. The utilization of serum, notwithstanding, prompts challenges in cleansing of antibodies. Advances, it is a costly innovation for expansive scale creation of hybridoma cells for mechanical generation of monoclonal antibodies. In perspective of these challenges, serum free media are in effect progressively utilized for refined hybridoma cells. (6, 7) Advantages of Serum Free Media in Hybridoma Cell Culture and Preparation of Monoclonal Antibodies: (6, 7) 1. Enormously rearranged sanitization of antibodies because of expanded 1.initial immaculateness and nonappearance of debasing immunoglobulin. 2. Diminished fluctuation of culture medium. 3. Diminished danger of irresistible operators. 4. Less factors for quality control/quality confirmation. 5. Expanded control over bioreactor conditions. 6. Potential for expanded counter acting agent emission. 7. Low or no reliance on creatures. 8. Financially savvy. 9. General upgraded productivity Disadvantages of Serum Free Media in Hybridoma Cell Culture and Preparation of Monoclonal Antibodies-1. Not all serum free media are material to all cell lines. 2. Cells may not develop to as high densities and might be more delicate than cells in serum 3. Media may take more time to plan. Bypassing Hybridomas and Cloning of mab Genes – The VH and VL qualities for antibodies can be enhanced through

polymerase chain response (PCR) utilizing 'all inclusive groundworks' (general preliminaries will convey monitored successions for generally antibodies). By building limitation locales in the above preliminaries, the enhanced VH and VL qualities can likewise be cloned specifically for expression in mammalian cells or microbes. The crude material for PCR might be hybridomas or B cells, which might be homogeneous (if gotten from single cells) or heterogeneous. In the last case, an assortment of VH and VL qualities will be intensified and will consolidate indiscriminately to create upwards of 106 clones for neutralizer qualities (from 1000 diverse VH and 1000 distinctive VL qualities). These qualities will be cloned in a phage and their items (especially Fab sections) can be screened for antigen restricting exercises. From such a substantial number of blends in a combatorial library, it is exceptionally hard to recuperate the first combines of V qualities (e.g. VHa.VLa or VHx.VLx is a unique match: VLy is another mix VHa). Be that as it may, the many-sided quality might be decreased by utilizing antigen-chose B lymphocytes (channels covered with antigen can be utilized for screening). (7) Designing and Building of mab Genes – The antigen restricting destinations of antibodies have been contemplated in some detail as of late. This prompted demonstrating of totally new antibodies, here and there for their utilization as proteins. This demonstrating through PC illustrations can be utilized for adjustment of neutralizer qualities or for union of altogether qualities. These qualities can be cloned and communicated in microscopic organisms. The antibodies delivered can be tried for their specificity and liking for particular antigen. (7) Primary and Secondary Libraries for Antibody Genes – In this technique a collection of counter acting agent qualities can be set up by utilizing qualities that can be gotten from various distinctive sources including the accompanying (i) Rearranged V qualities from creatures got using PCR (with general preliminaries) (ii) New

V qualities got through quality change, a procedure received in fowls (iii) Rearranged qualities acquired from mRNA through turn around interpretation (iv) Designing altogether new V qualities or D sections. The following stride is to permit the outflow of library in microbes and screen antibodies for antigen restricting exercises.

Peptide Synthesis for Monoclonal form:

Custom monoclonal immune response generation at Cell Essentials ordinarily takes 4-6 months and is separated into 3 stages. The customer has the choice of ending the hybridoma generation before the start of the following stage. Cell Essentials won't continue to the following period of the venture without composed (email) affirmation from the customer. The customer is invoiced for each stage at its introduction. The measure of material required for vaccinations of 5 mice is 1mg to 1.5mg and an extra 0.8mg to 1mg is required for ELISA screening.⁹ Phase I: Immunization of 5 Balb/c mice including preinjection tail drains, antigen/adjuvant infusions, all antigen/adjuvant lifts, tail drains and ELISA to decide most noteworthy titer mouse to be utilized for cell combination. Time for this Phase is ~ 2 months and costs \$1,800(USD). Stage II: Fusion of spleen cells with myeloma cell line, plating the combination item into six 96 well plates, and assurance of those wells communicating antibodies to the antigen by ELISA examine. All immune response emitting states are secluded and exchanged to a 24 well plate, extended and a bit solidified. Immune response containing medium (3ml) of up to 12 ELISA-positive preclones* will be dispatched to the customer for assessment in the customer's particular application. Time for this Phase is ~ 3-4 weeks and costs \$2,900(USD). ⁹ Phase III: Cloning of positive (IgG emitting) wells. A greatest of 5** of the positives chose by the customer will be cloned by restricting weakening and isotyped. Clones will be extended, and 10 vials of each chose clone will be solidified. Medium (10ml)

from each clone and also the solidified vials will be transported to the customer. Time for this Phase is ~ 1.5 to 3 months and costs \$2,800(USD). ⁹ Total Cost for each venture is \$7,500(USD). Extra clones can be secluded and handled as in Phase III for \$350(USD)/Clone. The accomplishment of a custom hybridoma venture is reliant upon the antigenicity of the material provided by the customer. Cell Essentials can't ensure that the material provided by the customer will create a safe reaction adequate to warrant continuing to Phase II. Cell Essentials just ensures that the antibodies created by hybridomas created perceive

Monoclonal production: Custom monoclonal immune response generation at Cell Essentials ordinarily takes 4-6 months and is separated into 3 stages. The customer has the choice of ending the hybridoma generation before the start of the following stage. Cell Essentials won't continue to the following period of the venture without composed (email) affirmation from the customer. The customer is invoiced for each stage at its introduction. The measure of material required for vaccinations of 5 mice is 1mg to 1.5mg and an extra 0.8mg to 1mg is required for ELISA screening.⁹ Phase I: Immunization of 5 Balb/c mice including preinjection tail drains, antigen/adjuvant infusions, all antigen/adjuvant lifts, tail drains and ELISA to decide most noteworthy titer mouse to be utilized for cell combination. Time for this Phase is ~ 2 months and costs \$1,800(USD). Stage II: Fusion of spleen cells with myeloma cell line, plating the combination item into six 96 well plates, and assurance of those wells communicating antibodies to the antigen by ELISA examine. All immune response emitting states are secluded and exchanged to a 24 well plate, extended and a bit solidified. Immune response containing medium (3ml) of up to 12 ELISA-positive preclones* will be dispatched to the customer for assessment in the customer's particular application. Time for this Phase is ~ 3-4 weeks

and costs \$2,900(USD). 9 Phase III: Cloning of positive (IgG emitting) wells. A greatest of 5** of the positives chose by the customer will be cloned by restricting weakening and isotyped. Clones will be extended, and 10 vials of each chose clone will be solidified. Medium (10ml) from each clone and also the solidified vials will be transported to the customer. Time for this Phase is ~ 1.5 to 3 months and costs \$2,800(USD). 9 Total Cost for each venture is \$7,500(USD). Extra clones can be secluded and handled as in Phase III for \$350(USD)/Clone. The accomplishment of a custom hybridoma venture is reliant upon the antigenicity of the material provided by the customer. Cell Essentials can't ensure that the material provided by the customer will create a safe reaction adequate to warrant continuing to Phase II. Cell Essentials just ensures that the antibodies created by hybridomas created perceive

Conclusion: In diagnosis, pregnancy can be detected by assaying of hormones with monoclonal. Similarly, pathogens can be detected in a few hours sparing several days of culturing of cells earlier needed. Immunopurification involves separation of one substance from a mixture of very similar molecules. The Company's patented technology has the capacity to address major industrial needs for a faster, lower cost and better quality process. Many of the steps in making hybridomas are similar to those involved with NeoClone's ABL-MYC technology. Antibodies are proteins synthesized in blood against specific antigens just to combat and give immunity in blood. They can be collected from the blood serum of an animal. Such antibodies are heterogeneous and contain a mixture of antibodies (i.e., monoclonal antibodies). Therefore, they do not have characteristics of specificity. If a specific lymphocyte, after the isolation and culture in vitro, the becomes capable of producing a single type of antibody which bears specificity against specific antigen. It is known as 'monoclonal antibodies'. Due to

the presence of desired immunity, monoclonal antibodies are used in the diagnosis of diseases.

References

1. Bretton PR, Melamed MR, Fair WR, Cote RJ. Detection of occult micrometastases in the bone marrow of patients with prostate carcinoma. *Prostate*. 1994;25(2):108–14. 2
2. Kvalheim G. Detection of occult tumor cells in bone marrow and blood in breast cancer patients—methods and clinical significance. *Acta Oncol*. 1996a;35:13–8.
3. Kvalheim G. Diagnosis of minimal residual disease in bone marrow and blood in cancer patients--methods and clinical implications. *Acta oncologica (Stockholm, Sweden)*. 1998b;37(5):455–62.
4. Franklin WA, Shpall EJ, Archer P, Johnston CS, Garza-Williams S, Hami L, et al. Immunocytochemical detection of breast cancer cells in marrow and peripheral blood of patients undergoing high dose chemotherapy with autologous stem cell support. *Breast Cancer Res Treat*. 1996;41(1):1–13.
5. Ghosh AK, Mason DY, Spriggs AI. Immunocytochemical staining with monoclonal antibodies in cytologically "negative" serous effusions from patients with malignant disease. *J Clin Pathol*. 1983a;36(10):1150–3.
6. Ghosh AK, Spriggs AI, TaylorPapadimitriou J, Mason DY. Immunocytochemical staining of cells in pleural and peritoneal effusions with a panel of monoclonal antibodies. *J Clin Pathol*. 1983b;36(10):1154–64.
7. Bretton, PR, Melamed, MR, Fair, WR, Cote, RJ (1994). Detection of occult micrometastases in the bone marrow of patients with prostate carcinoma. *Prostate*. 25(2), 108-14.
8. Franklin, WA, Shpall, EJ, Archer, P, Johnston, CS, Garza-Williams, S, Hami, L, Bitter MA, Bast RC, Jones, RB (1996). Immunocytochemical detection of breast cancer cells in marrow and peripheral blood

- of patients undergoing high dose chemotherapy with autologous stem cell support. *Breast Cancer Res Treat.* 41(1), 1-13.
9. Ghosh, AK, Spriggs, Al, Taylor-papadimitriou, J and Mason, DY(1983). Immunocytochemical staining of cells in pleural and peritoneal effusions with a panel of monoclonal antibodies. *J Clin Pathol*, 36,1154- 1164.
 10. Kvalheim, G (1996). Detection of occult tumour cells in bone marrow and blood in breast cancer patients—methods and clinical significance. *Acta Oncol*, 35, 13-8.
 11. <http://www.molecular-plant-biotechnology.info/hybridoma-and-monoclonal-antibodies-mabs/raising-theantibodies.htm>
 12. Elements of biotechnology, P.K. GUPTA (1st EDITION): 2006-2007, (203-211)
 13. Laboratory for Plague Microbiology, Department of Infectious Diseases, State Research Center for Applied Microbiology and Biotechnology, 142279 Obolensk, Serpukhov District, Moscow Region, Russia
 14. Roilides E, Pizzo PA. Modulation of host defenses by cytokines: evolving adjuncts in prevention and treatment of serious infections in immuno compromised hosts. *Clin Infect Dis* 1992;15:508-24.
 15. Hybridoma Techniques 1980 EMBO, SKMB Course, Basel. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory.
 16. Mackenzie, Michael, Alberto Cambrosio, and Peter Keating 1987 “Scientific information and intellectual property: the case of the hybridoma/monoclonal antibody technique.” Paper presented at the 1987 meeting of the Society for Social Studies of Science, Worcester, MA.
 17. Knorr-Cetina, Karin D. 1981 the Manufacture of Knowledge. New York: Pergamon Press.
 18. Knorr.Cetina, Karin D. and Michael Mulkey, eds. 1983 *Science Observed: Perspectives on the Social Study of Science.* London: Sage.
 14. Latour, Bruno and Steve Woolgar 1979 *Laboratory Life: The Social Construction of Facts.* Beverly Hills, CA: Sage
 19. Callon, Michel and Bruno Latour 1986 “Les paradoxes de la modernité: comment concevoir les innovation?” *Prospective et Sante Hiver*: 13-25.
 20. Lynch, Michael 1985 *Art and Artifact in Laboratory Science.* London: Routledge & Kegan Paul.
 21. Lynch, Michael 1982 “Technical Work and Critical Inquiry: Investigations in a Scientific Laboratory.” *Social Studies of Science* 12:499-533.
 22. Art To Science In Tissue Culture 1983 “Cell fusion with P.E.G.: is it reproducible?” *Art to Science in Tissue Culture* 2:1-2.
 23. Mumford RS, Murphy TV. Antimicrobial resistance in *Streptococcus pneumoniae*: can immunization prevent its spread. *J Invest Med* 1994; 42:613-21.
 24. Canadian Food Inspection Agency, Animal Diseases Research Institute, P.O. 640, Township Road 9-1, Lethbridge, AB T1J 3Z4, Canada
 25. C:\Documents and Settings\Admin\My Documents \Cell Essentials.mht
 26. http://www.attana.com/attana-files/Articles/AttanaIPT_29.pdf
 27. C:\Documents and Settings\Destiny\My Documents \History.htm
 28. C:\Documents and Settings\Destiny\My Documents \humane hybridoma technology Kenta Biotech.htm